MCS - Lifespan Edge - Page 2 of 3

Author: MCS

Aging Research

A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood

/ by MCS | Leave a Comment

This study explores the effects of young blood plasma on aging at the epigenetic level in rats, specifically examining whether plasma treatment can alter the epigenetic clock, a key molecular biomarker of aging. It examines the effects of heterochronic blood exchange (the transfer of blood between young and old mice) on tissue rejuvenation, without the […]

Read more

Aging Research

Reversing age: dual species measurement of epigenetic age with a single clock

/ by MCS | Leave a Comment

This study explores the effects of young blood plasma on aging at the epigenetic level in rats, specifically examining whether plasma treatment can alter the epigenetic clock, a key molecular biomarker of aging. Researchers developed six epigenetic clocks based on DNA methylation for various rat tissues, including pan-tissue, brain, liver, and blood clocks, as well […]

Read more

Aging Research

Old plasma dilution reduces human biological age: a clinical study

/ by MCS | Leave a Comment

This study extends findings from animal research on blood heterochronicity to humans, introducing a direct measure of biological age based on changes in 10 specific protein biomarkers. It supports the idea that human aging is driven by an accumulation of systemic molecular imbalances, which can be reduced to reverse biological age. The research shows that […]

Read more

Brain Health Research

Complementary analyses of the AMBAR trial: Impact of discontinuations, consistency of results across outcomes and additional adjustments

/ by MCS | Leave a Comment

The AMBAR study analyzed the effects of plasma exchange (PE) with albumin (with or without intravenous immunoglobulin, IVIG) on mild-to-moderate Alzheimer’s disease (AD) patients. Of the 496 patients enrolled, 347 were randomized into three treatment groups (different doses of albumin and IVIG) and a placebo group. Results showed that PE slowed cognitive and functional decline […]

Read more

Brain Health Research

Plasma Replacement Shows Success in Mild to Moderate Alzheimer Disease

/ by MCS | Leave a Comment

The AMBAR (Alzheimer Management by Albumin Replacement) study by Grifols demonstrated that plasma exchange (PE) with albumin and immunoglobulin replacement could delay cognitive and functional decline in patients with mild-to-moderate Alzheimer’s disease (AD). Over a 14-month period, 347 patients received PE treatment, which involved six weeks of weekly PE sessions followed by 12 months of […]

Read more

Brain Health Research

Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer’s disease?

/ by MCS | Leave a Comment

Therapeutic plasma exchange (TPE) is being explored as a treatment for Alzheimer’s disease (AD) to remove toxic or aging-related factors from the blood. Preclinical studies showed that injecting plasma from young mice into AD mice improved cognitive function, even though it did not reduce brain amyloid plaques. Early clinical trials, including a small study with […]

Read more

Brain Health Research

Emerging insights into the role of albumin with plasma exchange in Alzheimer’s disease management

/ by MCS | Leave a Comment

Alzheimer’s disease (AD) is a neurodegenerative condition marked by cognitive decline and eventually death. The main pathological features of AD include amyloid-β (Aβ) plaques and neurofibrillary tangles, but oxidative stress and inflammation are also major contributors to AD progression. Current pharmacologic treatments only address symptoms, and many trials targeting amyloid and non-amyloid pathways have failed. […]

Read more

Brain Health Research

Longitudinal lipidomic analyses in patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s disease

/ by MCS | Leave a Comment

This study from the AMBAR trial investigated the effects of plasma exchange with albumin replacement (PE-Alb) on lipidomic profiles in patients with mild-to-moderate Alzheimer’s disease (AD). Since lipid differences are known between AD patients and healthy individuals, this study aimed to see if PE-Alb could impact lipid biomarkers associated with AD. Methodology: Key Findings: Conclusion: […]

Read more

Brain Health Research

Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer’s disease in the AMBAR study

/ by MCS | Leave a Comment

The AMBAR study examined the feasibility and safety of plasma exchange (PE) with albumin replacement in patients with mild-to-moderate Alzheimer’s disease (AD). Patients received six weeks of weekly therapeutic plasma exchange (TPE) followed by monthly low-volume plasma exchange (LVPE) for 12 months. Key Findings: Conclusion: The TPE and LVPE procedures used in the AMBAR study […]

Read more

Brain Health Research

Inflammatory biomarkers in patients undergoing therapeutic plasma exchange with albumin replacement as a treatment for Alzheimer’s disease

/ by MCS | Leave a Comment

This study from the AMBAR (Alzheimer Management by Albumin Replacement) phase 2b/3 trial examined the effects of plasma exchange with albumin replacement (PE-Alb) on inflammatory biomarkers in mild-to-moderate Alzheimer’s disease (AD) patients. The goal was to investigate how PE-Alb, which aims to remove neurotoxic amyloid-beta and other pathological substances from the bloodstream, influences inflammation—potentially contributing […]

Read more

Brain Health Research

Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study

/ by MCS | Leave a Comment

This study, part of the AMBAR phase 2b/3 clinical trial, investigated structural and functional brain changes in Alzheimer’s disease (AD) patients treated with therapeutic plasma exchange (PE) with albumin replacement. The trial included mild-to-moderate AD patients randomized into four groups: three receiving PE with varying doses of albumin (with or without intravenous immunoglobulin, IVIG) and […]

Read more

Brain Health Research

P57 Mapping Quality of Life – Alzheimer’s Disease (QOL-AD) Scores to EQ-5D-5L Utilities in the Ambar Trial Population

/ by MCS | Leave a Comment

The AMBAR trial assessed the health-related quality of life (HRQoL) impact of plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease (AD) patients. Using data from the disease-specific Quality of Life-Alzheimer’s Disease (QoL-AD) questionnaire, EQ-5D-5L utilities were mapped with a model developed by Rombach et al. (2020) to estimate utility values for health economic evaluations. […]

Read more

To top